On the podcast, Biocon Executive Chairperson Kiran Mazumdar-Shaw said the firm disrupted the global insulin market. "Recombinant human insulin sold at ₹1,000 a vial; we brought it down to ₹100," she said. Western firms had to cut prices too, she added. Biocon is now the world's third-largest insulin maker.